Sunitinib-Induced Congestive Heart Failure in a Patient with Gastrointestinal Stromal Tumor.
Wala Ben Kridis-RejebSonda MasmoudiSalma CharfeddineAfef KhanfirPublished in: Archives of Iranian medicine (2022)
Common cardiovascular toxicities of sunitinib mainly include hypertension, QT prolongation, left ventricular dysfunction (LVD) and less frequently, congestive heart failure (CHF). Here, we report the case of a 67-year-old woman who developed heart failure after 24 months of sunitinib. Our case highlights the importance of strict and regular cardiovascular monitoring during sunitinib. It also shows that the reintroduction of sunitinib with maintaining heart failure treatment can be safe. The exact mechanisms of this cardiotoxicity have not been understood. There is no protective therapy available. Therefore, further investigations are needed in these areas. Medical specialists who prescribe and treat patients with sunitinib should be aware of the possible occurrence of these conditions and perform regular checkup of sunitinib-treated patients.
Keyphrases
- heart failure
- metastatic renal cell carcinoma
- renal cell carcinoma
- left ventricular
- cardiac resynchronization therapy
- blood pressure
- atrial fibrillation
- end stage renal disease
- newly diagnosed
- ejection fraction
- drug induced
- acute myocardial infarction
- stem cells
- risk assessment
- prognostic factors
- mitral valve
- percutaneous coronary intervention
- peritoneal dialysis
- aortic stenosis
- density functional theory
- smoking cessation
- patient reported
- replacement therapy